MRC1 and cancer: Two phase II clinical trials investigating the efficacy of PD-1 blockade in MSI-high/defective MMR tumors refractory to prior therapy including ECs have found that pembrolizumab is highly effective in MMR-deficient cancers in terms of RR, PFS, and overall survival [76, 77].